A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.

HepaStem (heterologous human adult liver-derived mesenchymal stem cells) - Promethera Biosci

http://www.ncbi.nlm.nih.gov/pubmed/34169246

Jun 29, 2021